Good MorningThe equities market got another shot of anti-viral medication on Thursday when Jerome Powell announced major changes in how the Federal Reserve views inflation. Instead of taking inflation at face value, the committee will use an average-inflation approach in an effort to help sustain economic growth. Under the new policy, inflation could run well above the 2.0% target before any policy action or business-stifling rate increases would be taken.
The Fed changes are intended to sustain and accelerate economic growth in the U.S. and the markets responded favorably. The Dow Jones Industrial Average led the days advance with a gain near 1.0% to set a new high for 2020. The S&P 500 and NASDAQ Composite posted smaller advances but both set new highs as well. Investors should expect to see more new highs so long as the data remains favorable.
Featured: Is Elon's empire crumbling? (Ad) 
|
Markets | | |
It’s always good to find a bargain. And it’s especially good to make a dollar stretch further in uncertain economic times like these. That formula is working for Ollie’s Bargain Outlet (NASDAQ:OLLI). And investors will find out how well the discount chain is doing when they repor... Read the Full Story |
|
From Our Partners | | CPA and CFA says you have WAY too many stocks - just buy these 3
After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%. | | Click here to view… |
|
Markets | | | JD.com Inc (NASDAQ:JD) is the 2nd largest e-commerce company in China and looks like a strong buy at this time. The company reported strong earnings recently and is hitting new all-time highs as a result. Read the Full Story |
|
Markets | | | One sector that has been a big winner throughout the novel coronavirus pandemic has been the discount retail sector. The discount retail sector is a $95 billion sector. Names like Walmart (NYSE:WMT) and Target (NYSE:TGT) are among the first to come to mind when consumers think low prices. But they a... Read the Full Story |
|
|
Markets | | |
The superhero streaming wars is heating up between Walt Disney’s (NYSE: DIS) Marvel Cinematic Universe (MCU) versus AT&T’s Warnermedia’s (NYSE: T) DC Extended Universe (DCEU). For those not familiar with superhero universes, Marvel Studios broke the mold along with all box of... Read the Full Story |
|
Markets | | |
It might be hard to reconcile how a large number of analysts are expecting a stock's price to fall, substantially, yet at the same time be worth buying, but sometimes, that's exactly the case. That's just what's going on with Qorvo (NASDAQ:QRVO), which is turning in big expectations in pretty much... Read the Full Story |
|
From Our Partners | | New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | | See Altucher’s Trump crypto prediction here |
|
The Early Bird Stock Of The Day Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. | | View Today's Stock Pick |
|
